Fingolimod after natalizumab and the risk of short-term relapse
Vilija G Jokubaitis, Vivien Li, Tomas Kalincik, Guillermo Izquierdo, Suzanne Hodgkinson, Raed Alroughani, Jeannette Lechner-Scott, Alessandra Lugaresi, Pierre Duquette, Marc Girard, Michael Barnett, Francois Grand'Maison, Maria Trojano, Mark Slee, Giorgio Giuliani, Cameron Shaw, Cavit Boz, Daniele LA Spitaleri, Freek Verheul, Jodi Haartsen Show all
NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod. METHODS: Data were obtained from the MSBase Registry. Relapse rates (RRs) for each patient group were compared using adjusted negative binomial regression. Survival analyses coupled with adjusted Cox regression were used to model predictors of time to first relapse on fingolimod. RESULTS: A total of 536 patients (natalizumab-fingolimod [n = 89]; IFN-β/GA-fingolimod [n = 350]; naive-fingoli..View full abstract
Awarded by NHMRC
Supported by a project grant from the NHMRC (1032484) and by the MSBase Foundation, a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis, Bayer, Genzyme, Sanofi, and Bio-CSL.